Table 4.
Multivariable logistic regression for in-hospital morbidity among patients undergoing ERCP (NIS 2016–2022, weighted design; AUC = 0.73)
| Variable | OR (95% CI) | p-value |
|---|---|---|
| Age (per 10-year increase) | 1.68 (1.67–1.68) | < 0.05 |
| Female sex | 0.88 (0.87–0.89) | < 0.05 |
| Type 2 diabetes | 1.20 (1.19–1.21) | < 0.05 |
| Chronic obstructive pulmonary disease | 1.06 (1.04–1.08) | < 0.05 |
| Morbid obesity | 1.14 (1.12–1.16) | < 0.05 |
| High-risk comorbidity group | 3.22 (3.18–3.26) | < 0.05 |
| Chronic kidney disease | 2.54 (2.50–2.58) | < 0.05 |
| Chronic heart failure | 2.84 (2.79–2.88) | < 0.05 |
| Liver cirrhosis | 2.26 (2.22–2.31) | < 0.05 |
| Elective admission | 0.93 (0.91–0.94) | < 0.05 |
| Diagnostic ERCP | 0.83 (0.81–0.85) | < 0.05 |
| Pancreatic cancer | 0.96 (0.94–0.97) | < 0.05 |
| Choledocholithiasis | 0.84 (0.83–0.85) | < 0.05 |
| Chronic pancreatitis | 0.81 (0.79–0.82) | < 0.05 |
| Acute necrotizing pancreatitis | 2.33 (2.24–2.43) | < 0.05 |
| Bile duct perforation | 4.26 (3.80–4.77) | < 0.05 |
| Choleperitonitis | 10.62 (9.70–11.64) | < 0.05 |
| Duct cancer | 1.02 (0.93–1.11) | 0.74 |